Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer
Authors
De Ruysscher, DFaivre-Finn, Corinne
Nackaerts, K
Jordan, K
Arends, J
Douillard, JY
Ricardi, U
Peters, S
Affiliation
Maastricht University Medical Center, Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht, The NetherlandsIssue Date
2020
Metadata
Show full item recordAbstract
Concurrent chemotherapy and radiotherapy (CCRT) followed by durvalumab immune therapy in appropriate patients is considered to be the standard of care in most fit stage III non-small-cell lung cancer (NSCLC) patients. However, CCRT is a toxic treatment that affects all organ systems and may cause acute and permanent side effects, some of which may be lethal. Supportive care is therefore of utmost importance in this clinical setting. A group of experts from the European Society for Therapeutic Radiology and Oncology (ESTRO) and the European Society of Medical Oncology (ESMO) identified the following items of importance for further improvement of supportive care: smoking cessation; nutrition before and during CCRT (including treatment and prevention of anorexia); physical exercise before and during CCRT; prevention and treatment of acute esophagitis and dysphagia; treatment of cough and dyspnea; treatment of skin reactions; treatment of fatigue; prophylaxis of nausea and emesis; prevention, diagnosis, and treatment of cardiac disease and damage; and optimization of radiotherapy techniques and chemotherapy adjustments to reduce toxicity in the era of immune therapy. The resulting recommendations are summarized in this manuscript and knowledge gaps identified, in which future investments are needed to improve supportive care and hence quality of life and survival for our stage III NSCLC patients.Citation
De Ruysscher D, Faivre-Finn C, Nackaerts K, Jordan K, Arends J, Douillard JY, et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 2020;31(1):41-9.Journal
Annals of OncologyDOI
10.1016/j.annonc.2019.10.003PubMed ID
31912794Additional Links
https://dx.doi.org/10.1016/j.annonc.2019.10.003Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2019.10.003
Scopus Count
Collections
Related articles
- Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
- Authors: Bi N, Liang J, Zhou Z, Chen D, Fu Z, Yang X, Feng Q, Hui Z, Xiao Z, Lv J, Wang X, Zhang T, Wang X, Deng L, Wang W, Wang J, Liu L, Hu C, Wang L
- Issue date: 2019 Dec 2
- [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
- Authors: Sun WZ, Song LP, Zhang YB, Ai T, Lu JL, Ren J, Gao Y
- Issue date: 2012 Mar
- Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
- Authors: Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C
- Issue date: 1998 Oct 1
- Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
- Authors: Hallqvist A, Wagenius G, Rylander H, Brodin O, Holmberg E, Lödén B, Ewers SB, Bergström S, Wichardt-Johansson G, Nilsson K, Ekberg L, Sederholm C, Nyman J
- Issue date: 2011 Feb
- Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
- Authors: Okawara G, Rusthoven J, Newman T, Findlay B, Evans W
- Issue date: 1997 Aug